[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369580-105":59,"doc-detail-369580-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","deep-plasma-proteomics-identifies-and-validates-an-eight-protein-biomarker-panel-that-separate-benign-from-malignant-tumors-in-ovarian-cancer","Deep plasma proteomics identiﬁes and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer","","Ovarian cancer has the highest mortality among gynecological malignancies and surgery is commonly used for final diagnosis, yet many symptomatic patients have benign conditions that could be managed more conservatively with reliable molecular triage. Deep plasma proteomics was applied to 5,416 plasma proteins across two Swedish cohorts of surgically diagnosed women. A discovery cohort trained multivariate risk-score models, then a replication cohort evaluated performance. The eight-biomarker panel separated benign from malignant tumors with high discrimination (AUC 0.96) and strong early-stage sensitivity.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deep-plasma-proteomics-identifies-and-validates-an-eight-protein-biomarker-panel-that-separate-benign-from-malignant-tumors-in-ovarian-cancer/369580/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deep-plasma-proteomics-identifies-and-validates-an-eight-protein-biomarker-panel-that-separate-benign-from-malignant-tumors-in-ovarian-cancer/369580.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a molecular test needed for ovarian cancer diagnosis?","Question",{"text":112,"@type":113},"Imaging can be inconclusive, and surgery is commonly required for confirmation. Many symptomatic cases are benign, so accurate molecular triage could reduce unnecessary surgery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the eight-protein biomarker panel developed and validated?",{"text":117,"@type":113},"The study analyzed 5,416 plasma proteins in two independent cohorts. Models were trained in a discovery cohort and evaluated in a replication cohort using performance metrics.",{"name":119,"@type":110,"acceptedAnswer":120},"How well did the panel perform in separating benign from malignant tumors?",{"text":121,"@type":113},"In the replication cohort, the model achieved an AUC of 0.96 and an early-stage sensitivity estimate of 91% at 68% specificity.",{"name":123,"@type":110,"acceptedAnswer":124},"What do the findings suggest about benign cases?",{"text":125,"@type":113},"The authors conclude that up to one third of benign cases can be identified using molecular measures, potentially reducing the need for diagnostic surgery.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369580,1790224758,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","A Nature Portfolio journal  \n[https://doi.org/10.1038/s43856-025-00945-0](https://doi.org/10.1038/s43856-025-00945-0)  \n\n| Deep plasma proteomics identiﬁes and validatesan eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer\u003Cbr> Check for updates |  |  |\n| --- | --- | --- |\n| Mikaela Moskov1, Julia Hedlund Lindberg1, Maria Lycke2, Emma Ivansson 1, Ulf Gyllensten 1, Karin Sundfeldt2, Karin Stålberg 3 & Stefan Enroth 1  |  |  |\n| Abstract |  | Plain language summary |\n| Background Ovarian cancer has the highest mortality of all gynecological cancers and surgery is commonly used as ﬁnal diagnostic. Available literature indicates that women with benign tumors could often be conservatively managed, but accurate molecular tests are needed for triaging when gold-standard imaging techniques are inconclusive or lacking. Methods Here, we analyzed 5416 plasma proteins in two independent cohorts (N1 = 171, N2 = 233) with women surgically diagnosed with benign or malignant tumors. Using one cohort as discovery, we compared protein levels of benign tumors with early stage (I–II), late stage (III–IV) or any stage (I–IV) ovarian cancer and trained risk-score reporting multivariate models including a ﬁxed cut-off for malignancy. Associations and model performance was then evaluated in the replication cohort.\u003Cbr>Results We identify 327 biomarker associations, corresponding to 191 unique proteins, and replicate 326 (99.7%) . By comparing the 191 proteins with their corresponding tumor gene expression we ﬁnd that only 11%(21/191) have signiﬁcant correlation. Through analyzes of protein-protein correlation networks, we ﬁnd that 62 of the 191 proteins have high correlation with at least one other protein, suggesting that many of the associations are secondary effects. In the replication cohort, our model has areas under the curve\u003Cbr>(AUC = 0.96) corresponding to 97% sensitivity at 68% speciﬁcity. For early-stage tumors, we estimate the sensitivity to 91% at a speciﬁcity of 68% as compared to 85% and 54% for CA-125 alone.\u003Cbr>Conclusions Our results indicates that up to one third of benign cases can be identiﬁed by molecular measures thereby reducing the need for diagnostic surgery. |  | Ovarian cancer is the deadliest of all gynecological cancers, and surgery is commonly needed to get a conﬁdent diagnosis. The majority of women with symptoms have non-cancerous (benign) conditions that could be more conservatively managed. If available, accurate molecular tests could tell cancer from non-cancer without surgery. Here, we have looked at over 5400 blood protein markers in two Swedish cohorts. We detected and validated many markers in symptomatic women and found that a test based on eight biomarkers showed excellent performance in separating benign from malignant tumors regardless of tumor type and could have clinical use when classifying symptomatic women. |\n| Ovarian cancer is the deadliest ofall gynecological cancers and the8th most common female cancer overall, with over 300,000 new cases and 200,000 deaths per year1. Discovery is mainly symptom-driven or by incidental ﬁnding2, and there are no biomarkers available today that could justify general screening3. The common late-stage diagnosis leads to an overall 5-year survival of ovarian cancer of only 30–50%. However, if the cancer is detected in stageI, close to 90% ofpatients can be cured, while patients with | spread cancers detected in stage III or IV has a 5-year survival rate of less than 30%4. Few molecular biomarkers are clinically used today to complement imaging examinations, but none have sufﬁcient accuracytobe used for screening or for accurate diagnostics in symptomatic women. Recent investigations based on single-cell mRNA sequencing have shown patientspeciﬁc gene expression patterns, speciﬁc changes in both gene-expression in the surrounding tumor micro-environment, as well as cell-type |  |\n\n1Department of Immunology, Genetics, and Pathology, Biom","cbCaie5IjlCmycn9","https://ap.wps.com/l/cbCaie5IjlCmycn9","pdf",1312452,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"Why is a molecular test needed for ovarian cancer diagnosis?\",\"answer\":\"Imaging can be inconclusive, and surgery is commonly required for confirmation. Many symptomatic cases are benign, so accurate molecular triage could reduce unnecessary surgery.\"},{\"question\":\"How was the eight-protein biomarker panel developed and validated?\",\"answer\":\"The study analyzed 5,416 plasma proteins in two independent cohorts. Models were trained in a discovery cohort and evaluated in a replication cohort using performance metrics.\"},{\"question\":\"How well did the panel perform in separating benign from malignant tumors?\",\"answer\":\"In the replication cohort, the model achieved an AUC of 0.96 and an early-stage sensitivity estimate of 91% at 68% specificity.\"},{\"question\":\"What do the findings suggest about benign cases?\",\"answer\":\"The authors conclude that up to one third of benign cases can be identified using molecular measures, potentially reducing the need for diagnostic surgery.\"}]","Deep plasma proteomics identiﬁes and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer | PDF",1790183534,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e36f2786ef0c3bc496ecc27113f69204.webp",983,1305,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2845ea7d7f8a83de9c717b6a4c4570d1.webp",982,1304,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d64c27371f5e7f96e9bc5c05e684598c.webp",981,1303,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14372b8f0aa43cd1c9f62736c4eba32e.webp",980,1301]